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Abstract.
Background: US direct-to-consumer advertising spending for medicine has soared in recent decades. Advertising has been
shown to impact drug utilization. Most Alzheimer’s disease patients are above age 65 and may take a range of prescription
medications for various disease states.
Objective: To investigate how direct-to-consumer advertising is associated with the drug utilization of patients ≥ 65 years
old.
Methods: Using advertising expenditure data and Medicare Part D drug purchase claims, we performed regression analyses
for each of the highest-spending drugs and age group, with cumulative monthly spending as the predictor variable and
drug utilization as the response variable. For each drug, we ran a second set of regression analyses to determine if the
spending-utilization correlation showed a significant difference between the two patient age groups (older than 65, younger
than 65).
Results: For all 14 drugs in our study, advertising spending is positively correlated with utilization (p < 0.01) in both age
groups. For seven of the 14 drugs studied, the difference in the utilization of patients older than 65 and the utilization of
patients younger than 65 is statistically significant at a p < 0.01 level. The 65-and-older age bracket exhibits significantly
greater utilization for all seven of these drugs.
Conclusion: We find televised advertising for certain drugs to be associated with significantly stronger drug utilization
among seniors, as compared to younger patients. Alzheimer’s disease physicians should be aware of this result, in light of
the medications that patients may take for other disease states, particularly mood and mental health medications.
Keywords: Aged, direct-to-consumer advertising, drug utilization, health services for the aged, prescription drugs, public
health, television
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INTRODUCTION
Direct-to-consumer advertising (DTCA) is the
marketing of pharmaceutical products directly to
patients, rather than health care professionals. The
United States and New Zealand are the only coun-
tries that fully permit this practice, which spans
ISSN 1387-2877 © 2021 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (CC BY 4.0).
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print, radio, Internet, and television programming [1].
Direct-to-consumer advertising spending has soared
in recent decades [2]. Between 1997 and 2016, the
pharmaceutical industry increased its annual direct-
to-consumer advertising spend from $2.1B to $9.6B,
a surge that included an eightfold increase in the total
number of television ads [2].
Debates about direct-to-consumer advertising are
well-attended on both sides. Some proponents claim
that direct-to-consumer advertising lowers prescrip-
tion drug prices by increasing competition [1]. By
offering information about available treatments, adv-
ertising may empower patients to engage in educated
discussions with health care professionals or improve
health outcomes by encouraging patients to begin uti-
lizing appropriate drugs more quickly [1, 3]. Dir-
ect-to-consumer advertising has also been shown to
increase physician visits [4] and improve patient com-
pliance for certain medications [5].
On the other hand, advertising to patients rather
than health care professionals may raise ethical and
regulatory concerns. Critics of the practice charge
that direct-to-consumer advertising contributes to
prescription drug overuse and disease mongering [6],
increasing health care spending in the process. For
some conditions, direct-to-consumer advertising has
increased inappropriate prescriptions [7], resulting in
more adverse drug reactions [8].
Direct-to-consumer advertising patterns suggest
that the activity is unlikely to play a positive role in
promoting competition or lowering prices. In general,
pharmaceutical companies tend to use direct-to-con-
sumer advertising to promote drugs without competi-
tors in the market [9]. When no competitor exists,
advertising would do little to promote competition.
Advertising for a drug without competition may
inform patients about an innovative treatment option
[1], but advertising in this context may also help
create or maintain patient loyalty toward pharmaceu-
tical products that are not strictly necessary for their
ailment [6]. Moreover, advertising costs are simply
passed on to the patient in the form of higher prices
[10, 11].
When pharmaceutical companies do use direct-to-
consumer advertising in markets characterized by
both a brand and a generic version, the effects are
also unlikely to enhance competition and lower pri-
ces. Generic companies generally do not engage in
direct-to-consumer advertising, given their low profit
margins [12]. Thus, advertising for the brand alter-
native serves to push consumers toward the more
expensive choice, limiting the competitive benefit of
generics on the market [10]. Soaring advertisement
spending may also divert financial resources away
from pharmaceutical research and development [11].
Regulation of direct-to-consumer advertising in
the United States is limited. Although most adver-
tising is regulated by the competition agency, the
Federal Trade Commission, advertising of prescrip-
tion drugs is regulated by the U.S. Food and Drug
Administration (FDA) [1, 11]. The FDA requires that
drug advertisements convey a balanced disclosure
of a medication’s benefits and risks [10]. Pharma-
ceutical companies assert, however, that freedom of
speech insulates them from many content restrictions,
and the FDA to date has avoided wading into regu-
lating anything beyond such disclosures [13].
Tax rules also provide advantages for direct-to-
consumer advertising over other types of promotional
activities. In contrast to other pharmaceutical promo-
tion practices that are subject to spending caps, such
as physician detailing, direct-to-consumer advertise-
ment spending may be claimed as a tax deduction
[10, 14].
Most important, past research demonstrates that
direct-to-consumer advertising increases patient drug
utilization along two avenues. Some studies have
shown that advertising spending initiates new doc-
tor visits [4, 15], netting new prescriptions for cer-
tain drug classes [16, 17]. Other work has found that
advertising increases patient willingness to fill exist-
ing drug prescriptions [17]. Looking more broadly at
spending and utilization, direct-to-consumer adver-
tising has been shown simply to increase an adver-
tised drug’s sales [18]. To this end, some analyses
have attributed as much as 20–30% of American
prescription drug expenditure growth to direct-to-
consumer advertisement spending [17, 18]. Despite
this considerable work regarding the effects of adver-
tisement on drug utilization, however, the impact on
the drug utilization behaviors of senior citizens con-
stitutes a gap in the empirical literature. Our study
aims to help fill this gap.
Specifically, our study focuses on television to
examine how advertising shapes the drug utilization
of seniors. Since the FDA relaxed advertising content
regulations in 1997, television has become the prin-
cipal medium of direct-to-consumer advertising [1].
Television is particularly popular among senior citi-
zens (65 and older), who on average watch up to two
more hours of television daily than younger Ameri-
cans [19]. Finally, we focus on television because it
is a highly effective advertising medium: One study
of pharmaceutical spending found that broadcast
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advertising, which includes television ads, boosted
drug sales with twice the elasticity of non-broadcast
advertising [18].
Evidence of age-related declines in decision-
making and information processing raises particular
consumer protection concerns related to direct-to-
consumer advertising. Past surveys of older adults
exposed to direct-to-consumer advertising found that
older adults tend to notice and retain less informa-
tion about the advertised drug compared to younger
patients, including details about side effects, risks,
and whether the drug requires a prescription [20].
Older adults also tend to display poorer health numer-
acy [21] and health literacy [22]. Patients with lower
health literacy, in turn, are less likely to recognize the
names or purposes of medications they are prescribed
[23].
Older adults also are more susceptible to “illu-
sions of truth”, in which repeated false information
is believed true [24]. One study found that older
adults were more likely to misremember repeated
product warning claims as recommendations [25],
suggesting that advertising risk and benefits disclo-
sures may offer limited consumer protection benefit
to the elderly. Moreover, source, or context, memory
declines with age [25], meaning that seniors may be
at greater risk of recalling information dispensed by
a paid spokesperson as advice from a trusted health
care professional.
Qualities of television advertising may compound
cognitive deficits in older adults, so that prescription
drug marketing may be disproportionately effective
among older populations. For instance, the growing
frequency of televised drug ads [1, 2] could exac-
erbate seniors’ illusions of truth. The imagery of a
positive, post-treatment patient experience that in-
creasingly dominates televised prescription drug ads
[26] may complement the tendency of seniors to pri-
vilege positive information when engaged in deci-
sion-making [27]. Related to this point, past research
demonstrates that older adults, especially those with
cognitive deficits, consistently judge medications
more favorably when they are positively framed [28].
Finally, seniors are major stakeholders in the phar-
maceutical advertising conversation. The likelihood
of having a drug prescription increases with age
[20], as does the number of annual prescriptions per
individual [29]. Moreover, elderly prescription drug
usage—measured both in terms of median prescrip-
tions per individual and the proportion of older adu-
lts taking 5 or more medications—has grown dramat-
ically in recent decades [30]. The 2006 inauguration
of the Medicare Part D program, which offered
prescription drug coverage to all Americans over
65, has contributed to this trend [30], boosting
elderly prescription drug utilization rates by 12.8%
[31]. Pharmaceutical companies seem to understand
elderly usage patterns well and have used television
to capitalize on those patterns. For example, one anal-
ysis found that in the months following the passage
of Medicare Part D, elderly-dense areas experienced
greater exposure to televised pharmaceutical adver-
tising compared to areas with a younger population
[17].
With these advertising practices in mind, we att-
empt to examine how direct-to-consumer advertis-
ing is associated with seniors’ drug utilization. Past
research demonstrates that direct-to-consumer adver-
tising spending increases utilization of advertised
drugs [5, 15–18]. Our study does not attempt to show
that televised advertising spending causes stronger
drug utilization responses in seniors. Rather, we build
on these past analyses of advertising spending to
investigate associations between televised advertis-
ing spending and drug utilization by patients older
than 65 [5, 15–18].
METHODS
Data source for televised direct-to-consumer
advertising spending
We licensed advertisement expenditure and occur-
rence data from a media analytics agency, Kantar
Media. We then performed regression analyses on
trend reports generated from this data, filtering for
network and cable television advertising of pharma-
ceutical products between 2006–2017. Trend reports
returned the name of the advertised prescription drug,
along with the name of its manufacturer, its treatment
group, and the monthly amount spent on its televised
advertisement.
Data source for prescription drug utilization
We purchased data from the Centers for Medicare
and Medicaid Services on a cohort of roughly one
million Medicare patients in order to examine the
cohort’s Part D drug purchase claims filed during
the period of 2006–2017. To qualify for Medicare,
one must be 65 years or older, or be younger than
65 years old, and suffer from: a permanent disability,
amyotrophic lateral sclerosis, or permanent kidney
failure [32]. In 2006, the passage of Part D expanded
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Medicare services to include prescription drug cov-
erage [31].
All patients included in our cohort were enrolled
only in Medicare Part A (hospital), B (doctor & outpa-
tient), and D (prescription drug) coverage, excluding
Part C. While Part C (Medicare Advantage) plans
may also cover prescription drugs, the extent of
coverage is not uniform between plans, and some
Part C plans do not cover prescription drugs at all
[33]. The Part D dataset only included patients who
experienced at least one prescription drug event and
remained alive between 2006–2017. A prescription
drug event is a single instance of a patient filling a pre-
scription for a drug with exactly one corresponding
National Drug Code.
We divided our claims data into two patient sub-
populations. Patients younger than 65 comprised
35.7% of the total patient population, while patients
65 and older accounted for the remaining 64.3%. We
collapsed and aggregated the individual claims data
to reflect monthly utilization of each drug for each age
group. Monthly drug utilization refers to the number
of patients who used a specific drug in one month.
Prescription drug selection
We further filtered the trend reports generated
from Kantar to identify the five treatment groups
with the highest televised direct-to-consumer adver-
tising spending between 2006 and 2017. Although
the Impotence treatment group ranked second in total
televised advertising spending, we did not analyze
drugs in this group because Medicare Part D gen-
erally does not cover impotence medications [34].
To clarify our categories, we combined the drugs
treating depression and bipolar disorder into one
category—Mood and Mental Health. Consequently,
our study drew from four treatment groups: Arthri-
tis, Diabetes (Non-Insulin), High Cholesterol, and
the combined Mood and Mental Health category.
We selected the prescription drugs from these four
groups whose cumulative ad spending during the
study period exceeded $150 M (Table 1). We elected
to focus on high-spending drugs because, were we to
find that high-spending drugs are not associated with
greater drug utilization, then it would be reasonable
to conclude that lower-spending drugs likely bore lit-
tle influence on drug utilization, either. We note that
few drugs for the treatment of Alzheimer’s disease
have direct-to-consumer advertising during the study
period, and the advertising spending is relatively low
for those that do.
Our model only included the period of time
when, for each drug, no generic competitor was
present. Generic competition negatively and signifi-
cantly impacts branded drug utilization, which could
provide a confounding factor in the results [31].
Moreover, drug companies generally stop or reduce
advertising spending as generic competition arrives
on the market [9]. We defined a generic competitor
as a drug produced by another manufacturer with the
same active ingredient, dosage, and delivery method.
In the High Cholesterol treatment group, rosuvas-
tatin and atorvastatin are both high-intensity statins
[32]. To provide consistency within the model, we
stopped considering both rosuvastatin and atorvas-
tatin when a generic atorvastatin entered the market
in 2011 (Table 2).
Table 1
Drugs exceeding cumulative televised direct-to-consumer spending of $150M from treatment groups with highest televised direct-to-
consumer spending (2006–2017)
Trade Generic Drug Treatment Cumulative
Name Name Manufacturer Group Spending
1 Latuda Lurasidone Sumitomo Dainippon Pharma Mood and Mental Health $321.5M
2 Abilify Aripiprazole Otsuka Pharmaceutical Mood and Mental Health $528M
3 Cymbalta Duloxetine Eli Lilly Mood and Mental Health $785M
4 Humira Adalimumab AbbVie Arthritis $1.5B
5 Enbrel Etanercept Amgen Arthritis $662.5M
6 Xeljanz Tofacitinib Pfizer Arthritis $471.6M
7 Celebrex Celecoxib Pfizer Arthritis $447.5M
8 Trulicity Dulaglutide Eli Lilly Diabetes $222.9M
9 Victoza Liraglutide Novo Nordisk Diabetes $267.4M
10 Farxiga Dapagliflozin AstraZeneca Diabetes $265.2M
11 Jardiance Empagliflozin Boehringer Ingelheim Diabetes $152.2M
12 Invokana Canagliflozin Johnson & Johnson Diabetes $192.9M
13 Lipitor Atorvastatin Pfizer High Cholesterol $665.5M
14 Crestor Rosuvastatin AstraZeneca High Cholesterol $472.4M
Total $7.0B
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Table 2
Summary of findings
Drug Period of Significance Utilization Patient Percentage





than 65 than 65
Lurasidone‡ Jan. 2014 –Dec. 2017 Yes Increasing Increasing Increasing Older than 65 3.5
Aripiprazole Sep. 2007 – Mar. 2015 Yes Increasing Increasing Decreasing Older than 65 2.5
Duloxetine Apr. 2006 – Nov. 2013 Yes Increasing Increasing Increasing Older than 65 1.6
Adalimumab Jan. 2007 – Dec. 2014 Yes Increasing Increasing Increasing Older than 65 1.7
Etanercept Aug. 2006 – Dec. 2016 Yes Decreasing Decreasing Decreasing Younger than 65 1.2
Tofacitinib June 2013 – Dec. 2017 No Increasing Increasing Increasing Similar -
Celecoxib § Apr. 2007 –Nov. 2014 Yes Decreasing Decreasing Decreasing Younger than 65 3.3
Dulaglutide Oct. 2015 – Dec. 2017 No Increasing Increasing Increasing Similar -
Liraglutide Sep. 2013 – Dec. 2017 No Increasing Increasing Increasing Similar -
Dapagliflozin Sep. 2014 – Dec. 2017 No Increasing Increasing Increasing Similar -
Empagliflozin Sep. 2015 – Dec. 2017 No Increasing Increasing Increasing Similar -
Canagliflozin June 2014 – Nov. 2017 No Increasing Increasing Increasing Similar -
Atorvastatin Mar. 2006 – Sep. 2011 Yes Decreasing Decreasing Decreasing Younger than 65 1.1
Rosuvastatin Mar. 2006 – Sep. 2011∗∗ No Increasing Increasing Increasing Similar -
∗Drug names are color-coded by treatment group, with Mood & Mental Health (pink), Arthritis (green), Diabetes Non-Insulin (yellow), and
High Cholesterol (grey). †The time period that our regression models covered started from the first occurrence of televised ad spending for
a given drug and ended when spending ceased or when generic competition for the drug entered the market. Spending on televised ads for
the vast majority of brand drugs ended with the entrance of a competing generic. Generic competition also has a negative and significant
impact on the brand utilization; therefore, regardless of the magnitude of ad expenditures, utilization for a brand drug drops when there is
a competing generic. ‡How to read: lurasidone is a drug in the mood and mental health treatment group. The total number of patients on
lurasidone increased during this period, and the response percentage of older patients on lurasidone was 3.5 times higher than the response
percentage of younger patients on lurasidone. §How to read: celecoxib is a drug in the arthritis treatment group. The total number of patients
on celecoxib decreased during this period, and the response percentage of younger patients on celecoxib was 3.3 times lower than the
response percentage of older patients on celecoxib. ∗∗We assumed that rosuvastatin and atorvastatin were replaceable, since both drugs
are high-intensity statins. Because atorvastatin had a generic in the market much earlier than rosuvastatin, we considered atorvastatin’s
generic drug to be a competitor to rosuvastatin as well and therefore, considered rosuvastatin’s “end date” to coincide with the entrance of
atorvastatin’s generic.
Fig. 1. Direct-to-consumer televised advertising spending,
2006–2017. †† Graph shows total direct-to-consumer televised ad
spending for drugs with and without generic competitors, along
with total number of advertised drugs during the study period.
By including the drug count, we show that overall spending has
increased due to greater spending per drug, rather than a greater
number of advertised drugs.
In total, the 14 drugs we studied accounted for
more than $7 billion in cumulative televised adver-
tising spending between 2006–2017 (Table 1). This
constitutes 25.6% of all televised pharmaceutical
advertising spending during this period (Fig. 1).
Statistical analysis
First, we sought to determine the strength and char-
acter of the correlation between cumulative televised
advertising spending and the number of patients uti-
lizing the advertised drug each month. For each of the
14 drugs and for both patient subpopulations, we per-
formed regression analyses with cumulative monthly
spending as the predictor variable and drug utiliza-
tion as the response variable. Given that the response
variable is a discrete variable, we opted to use
Maximum Likelihood Estimation (MLE) rather than
an Ordinary Least Squares (OLS) regression. Due
to overdispersion in our initial Poisson regression
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models, we ran negative binomial regressions and
explored both linear and nonlinear relationships.
We chose between the linear (Formula 1) and non-
linear (Formula 2) models by performing a one-si-
ded Chi Squared Cumulative Density Function test
using the SciPy package in Python. If the inclu-
sion of the quadratic term was statistically significant
at a p < 0.01 level, we proceeded with the nonlin-
ear model; otherwise, we proceeded with the linear
model. Advertising spending values were divided
by 1000 to make quadratic terms feasible for each
regression model (Supplementary Table 1).
Formula 1. In (Patient Count for a given age
group) = α + β DTCA Spending + ε
Formula 2. In (Patient Count for a given age
group) = α + β1 DTCA Spending
+ β2 DTCA Spending2 + ε
Where DTCA Spending is cumulative and monthly
Next, we ran a second set of negative binomial
regressions (Formula 3) for each drug to determine if
the correlation between televised advertising spend-
ing and utilization was significantly different between
the two patient subpopulations.
Formula 3. In (Patient Count)
= α + β1 Dummy + β2 DTCA Spending
+ β3 Dummy ∗ DTCA Spending
+ β4 DTCA Spending2 + ε
Where DTCA Spending is cumulative and monthly
The bolded interaction term in Formula 3 helped us
determine whether the correlation between the drug
utilization of the two age groups and televised adver-
tising spending was significantly different. For each
drug, “Patient Count” in Formula 3 includes both
age groups. We assigned either “0” or “1” values
to the “dummy” variable for the older and younger
age groups, respectively. If the p-value of the inter-
action term coefficient was less than 0.01, then the
two age groups expressed significantly different drug
utilization linked to advertising spending; if not,
the difference between age groups was insignificant
(Supplementary Table 2).
In order to compare drug utilization correlations
between age groups, we added a baseline cumula-
tive spending of $100,000 to our initial regression
models and generated utilization data as a function
of cumulative advertising spending. To compare drug
utilization between the two age groups as a function
of advertising spending, we divided the count of the
larger change in patient group utilization by the count
of the smaller utilization change. With this, we could
quantify the relative strength of each group’s drug
utilization trend for each drug that displayed a signif-
icant age-related difference in utilization associated
with advertising spending (Table 2).
RESULTS
We observed that total spending for televised phar-
maceutical advertisements grew by more than $1
billion over the ten-year span, a roughly 44% increase
(Fig. 1). The surge was carried by the last three years
of the study period—2015, 2016, and 2017.
Although advertising spending accelerated, the
total number of advertised drugs changed little during
the study period (Fig. 1). Thus, we can observe that
television advertising spending per branded drug has
increased substantially, especially in recent years.
For 13 of the 14 drugs we analyzed, the utilization
behavior of the two patient subpopulations moved in
concert with one another. That is, when total utiliza-
tion was increasing, utilization by both seniors and
the under-65 population increased; when total utiliza-
tion was decreasing, utilization by both age groups
decreased. Aripiprazole was the only drug with a
conflicting utilization pattern: as patients under 65
were decreasing their utilization, patients older than
65 used the drug in greater numbers (Table 2).
Our first set of regression models demonstrated
that, for each of the 14 drugs, and both patient age
groups, there was a statistically significant correlation
between utilization and cumulative monthly televised
advertising spending, at a p < 0.01 level (Supplemen-
tary Table 1). Our second set of regression models
showed that, for seven of the 14 drugs, the difference
between the two patient groups’ utilization associ-
ated with cumulative monthly televised advertising
spending was statistically significant at a p < 0.01
level (Supplementary Table 2). These seven drugs
were: all three drugs in the Mood and Mental Health
treatment group, three of four drugs in the Arthri-
tis treatment group, and one of two drugs in the High
Cholesterol treatment group. None of the five drugs in
the Diabetes (Non-Insulin) treatment group showed
a statistically significant difference in utilization by
age bracket (Table 2).
For all seven drugs with significant age-related
differences in utilization, the correlation between
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cumulative televised advertising spending and drug
utilization in the 65-and-older subpopulation was sig-
nificantly stronger than for patients under 65. When
overall utilization of these drugs was increasing, the
percentage change in seniors’ utilization was signifi-
cantly greater than the percentage change in younger
patients’ utilization. Similarly, when overall utiliza-
tion of these drugs was decreasing, the percentage
change in utilization of patients 65 and older was
significantly smaller than the percentage change in
utilization of patients younger than 65.
For these seven drugs, in other words, seniors
demonstrated significantly greater spending-linked
utilization across the study period, no matter the
drug’s overall utilization trajectory. On one hand,
television advertising spending was associated with
seniors enrolling more vigorously when overall uti-
lization of a drug was increasing. For instance,
spending for the bipolar treatment lurasidone was
associated with a growth in prescriptions 3.5 times
greater among seniors compared to patients under
65 (Table 2). At the same time, our findings asso-
ciated advertising spending for a drug during periods
of decreasing overall utilization with seniors reduc-
ing their prescriptions more slowly than patients
under 65: utilization of the arthritis drug celecoxib by
patients under 65 dropped 3.3 times faster compared
to older patients’ utilization (Table 2).
DISCUSSION
For all 14 drugs we examined, we observed a sig-
nificant correlation between cumulative televised ad-
vertising spending and the drug utilization in both
patient age groups. This finding aligns with prior
research demonstrating that direct-to-consumer adv-
ertising spending increases drug utilization [5,
15–18].
We found that televised advertising for certain
drugs linked to significantly stronger drug utilization
among seniors, compared to younger patients. For
these seven drugs, the stronger age-related correlation
applied both to periods of increasing and decreasing
overall utilization. Although we cannot assert that
advertising causes seniors to respond with greater
drug utilization, the stronger correlation between
spending and seniors’ utilization of certain drugs
does suggests that televised advertising of prescrip-
tion drugs may influence seniors more than younger
viewers. Considering the cognitive decline [24, 25,
27], greater medication usage [20, 29, 30], and greater
consumption of television among senior populations
[19], the correlation we found highlights the potential
of televised direct-to-consumer advertising to unduly
influence seniors’ drug utilization behavior.
Several factors limit what our findings may assert
about the relationship between televised advertising
spending and the drug utilization of seniors. Our
regressions do not account for channels of direct-to-
consumer advertising other than television, which,
although challenged increasingly by the Internet as
a pharmaceutical advertising platform [1], channeled
an impressive growth in advertising spending during
the study period (Fig. 1). It is possible, however, that
younger patients may have better responded to adver-
tisements delivered through social media or other
platforms. Nor did our study cover pharmaceutical
promotion directed toward healthcare providers, such
as physician detailing, free samples, and scientific
journal advertisements. Including these predictors
with our direct-to-consumer advertising data would
return a more balanced, robust, and correctly speci-
fied model. Furthermore, we do not know what per-
centage of our cohort was exposed to televised
drug advertisements, nor how many discussed a
prescription with their physician after viewing adver-
tisements. Finally, we recognize the possibility that
increased patient utilization and drug sales may also,
in turn, encourage further advertising spending for
that drug. These factors limit us from claiming a
causal relationship between advertising spending and
drug utilization, as previous studies have [5, 15–18].
Limitations may also arise from the patient pop-
ulation and drugs we elected to study. Compared
to younger patients, physicians may be more reluc-
tant to discontinue a senior’s prescription if it is
working. Such therapeutic inertia could explain why
seniors decreased utilization of three drugs (etan-
ercept, celecoxib, atorvastatin) more slowly than
younger patients, but it would not explain seniors’
faster uptake observed in four other drugs (lurasidone,
aripiprazole, duloxetine, adalimumab) (Table 2).
Moreover, relying on Medicare data means that our
under-65 population—composed of patients with
permanent disabilities, amyotrophic lateral sclerosis,
or end-stage renal disease [32]—is not a represen-
tative sample of under-65 Americans. Compared to
the overall under-65 population, Medicare patients
younger than 65 may exhibit different drug uti-
lization patterns or engage differently with drug
advertisements. Future research may benefit from
more granular population data, incorporating factors
such as race and geography to more precisely study
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how direct-to-consumer advertising may affect dif-
ferent demographics.
Given that our study only includes drugs adver-
tised directly to consumers, we cannot compare
changes in utilization between advertised and non-
advertised drugs within a therapeutic group. We also
considered that the stronger correlation between
advertising spending and seniors’ drug utilization
could be caused by the age-related prevalence of dis-
eases treated with the drugs in our study. That is, we
considered whether seniors might display stronger
correlations for drugs treating diseases more preva-
lent in older populations, and weaker correlations for
drugs treating diseases less prevalent in older popu-
lations. If the age-related prevalence of a disease did
explain the correlation between advertising spending
and utilization of drugs treating that disease, then we
would expect to find that patients in the more suscepti-
ble age group express significantly greater utilization
for all drugs treating that disease.
As Table 2 illustrates, the data do not fully sup-
port that explanation. In fact, although depression
[37] and bipolar disorder [38] are more frequently
diagnosed in younger age groups, our study found
a stronger correlation between advertising spend-
ing and seniors’ utilization of all three drugs in the
mental health treatment group (Table 2). One should
note, however, that antipsychotics such as aripipra-
zole are also frequently prescribed to elderly patients
for conditions including dementia [39, 40]. Addition-
ally, seniors are disproportionately affected by type
2 diabetes [41], but all five of the diabetes drugs
showed comparable utilization rates linked to adver-
tising spending between age groups (Table 2). With
the high cholesterol drugs in our study, which are
more likely to be prescribed to seniors than younger
patients [42], only one of the two drugs’ spending was
associated with significantly higher drug utilization in
seniors (Table 2). Moreover, past study demonstrates
that direct-to-consumer advertising does positively
impact the utilization of cholesterol-lowering statins
[5].
Finally, although increases in advertising spending
for three of four drugs treating arthritis—an affliction
more prevalent in seniors [43]—correlated to signif-
icantly stronger senior utilization, spending for the
arthritis drug tofacitinib did not (Table 2). Thus, we
did not find that all drugs in any treatment group
uniformly exhibited stronger spending-related uti-
lization by the age group more likely to be treated
for the corresponding disease or ailment. Drugs that
treat an older-skewing disease may be used at higher
rates among older patients, but our findings do not
suggest that the age profile of a disease explains why
advertising spending for certain drugs is linked to
greater utilization by older patients.
In addition to the age-related differences between
patient utilization, therefore, our findings lend some
nuance to the landscape of prescription drugs. The
differences we observed between treatment groups
may propose further study in order to understand how
the consequences of direct-to-consumer advertising
vary according to the advertised drug. Paired with
a more granular understanding of prescription drug
use, this study may encourage advertising regulations
to consider for the treatment group of an advertised
drug.
The stronger correlation we observed between tele-
vised advertising spending in certain drug categories
and seniors’ drug utilization rates raises concerns
about the influence of direct-to-consumer adver-
tising on seniors. These findings propose further
investigation into how direct-to-consumer advertis-
ing shapes the drug utilization behaviors of elderly
patients. More robust models evaluating how pre-
scription drug advertising contributes to seniors’ drug
utilization—in addition to inappropriate prescrip-
tions and adverse drug reactions—will help inform
relevant regulatory and policy debates, in addition to
clinical best practices.
Direct-to-consumer advertising policy recommen-
dations could potentially take into account age-
related cognitive deficiencies, such as in regulating
the delivery of risk and side effect information, the
mode of advertising, or advertising frequency. Our
findings complement past research demonstrating
that older individuals with cognitive deficits display
less capable medical decision-making [44] and med-
ication adherence [45].
Our findings also suggest age-conscious clinical
guidelines for drug prescription policies. The influ-
ence of direct-to-consumer advertising on seniors
may be mitigated by proactive reviews of older
patients’ drug treatment regimens, particularly as
many patients accrue drug prescriptions with age [20,
29, 30]. Likewise, patient requests for specific drug
brands may prompt physicians to inquire about and
discuss a patient’s information source, in addition to
underlying symptoms.
Our findings may be particularly important to
physicians treating Alzheimer’s disease. Most Alz-
heimer’s disease patients are above age 65 [46], and
the study concludes that television advertising can
have an outsized impact on that age population.
R. Feldman / Physicians Treating Alzheimer’s Disease Patients 1177
Physicians treating Alzheimer’s disease patients
should be aware of this result, in light of the range
of drugs their patients may be taking for other
related and unrelated disease states. Of particular
importance, some of the strongest correlations we
found were for the mood and mental health disor-
der drugs, lurasidone, aripiprazole, and duloxetine.
With direct-to-consumer television advertising, the
response percentage of older patients who were on
lurasidone, aripiprazole, and duloxetine increased by
3.5, 2.5, and 1.6 times the response percentage of
younger patients taking these drugs. Neuropsychi-
atric symptoms are common in Alzheimer’s disease
patients. In addition, the disease states treated by
these drugs are several times higher for patients with
dementia than for patients without dementia [47, 48],
and neuropsychiatric symptoms, in general, are com-
mon in patients with Alzheimer’s disease [49, 50] and
diseases associated with dementia. Thus, this finding
should be of particular interest for physicians treating
Alzheimer’s disease and dementia patients.
Clinical prescription guidelines could complement
existing spending transparency rules to better situ-
ate physicians as mediators of the drug information
advertised directly to consumers. Recognizing the
clinical implications of this research will help ensure
that advertising improves health care access and
literacy without exploiting vulnerable populations,
such as the elderly, in the process. Drawing on past
research of age-related cognitive decline and the
effects of direct-to-consumer spending, we find here
that televised pharmaceutical advertising may have
an outsized impact on senior citizens.
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